<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809782</url>
  </required_header>
  <id_info>
    <org_study_id>Two-stage liver</org_study_id>
    <nct_id>NCT01809782</nct_id>
  </id_info>
  <brief_title>Cognitive Outcome After Two-stage Liver-Operation</brief_title>
  <acronym>2-StaLi</acronym>
  <official_title>Post-operative Cognitive Dysfunction (POCD) and Delirium in Patients Undergoing Two-stage Liver Operation - a Pilotstudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive outcome (delirium and post-operative cognitive deficiency) in patients undergoing
      two-time liver resection.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 11, 2013</start_date>
  <completion_date type="Actual">August 10, 2017</completion_date>
  <primary_completion_date type="Actual">April 16, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>POCD</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Measured by Cambridge Neurophysiological Test Automated Battery (CANTAB); calculated in relation to a healthy control group without intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delirium</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Measured by Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Measured by Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) and Confusion Assessment Method (CAM) and Intensive Care Delirium Screening Checklist (ICDSC) and Delirium Detection Scale (DDS) and Delirium Rating Scale (DRS) and The Nursing Delirium Screening Scale (NU-DESC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of POCD</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Measured by Cambridge Neurophysiological Test Automated Battery (CANTAB) calculated in relation to a healthy control group without intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplifies Acute Physiology Score (SAPS II)</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Simplifies Acute Physiology Score (SAPS II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>Post-anaesthesia Discharge Scoring Stay (PADSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative intensive care unit stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Criteria of internal standard operating procedures (SOP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>Measured by Numeric Rating Scale (NRS) or Verbal Rating Scale (VRS) or Visual Analogue Scale (VAS) or Behavioural Pain Scale (BPS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of post-operative organ dysfunctions and complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic inflammatory response syndrome (SIRS) and infection</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
    <description>Centers for Disease Control (CDC) and American Thoracic Society (ATS) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 36-item short form health survey (SF-36)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>36-item short form health survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 90 days, after 182 days and after 365 days</time_frame>
    <description>postoperative survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiological and Chronic Health Evaluation (Apache II)</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Acute Physiological and Chronic Health Evaluation (Apache II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequental Organ Failure Assessment (SOFA)</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Sequental Organ Failure Assessment (SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TISS</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Therapeutic Interventions Scoring System (TISS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RASS</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Richmonds Agitation Sedations Scale (RASS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCS</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Glasgow Coma Scale (GCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RIFLE criteria</measure>
    <time_frame>At postoperative day 7 after second liver operation</time_frame>
    <description>Risk Injury Failure Loss End Stage Kidney Disease (RIFLE = risk (R), injury (I), and failure (F), sustained loss (L) and end-stage kidney disease (E))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of EuroQoL instrument (EQ-5D)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>EuroQoL instrument (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Barthel Index(for Activities of Daily Living, ADL)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Barthel Index (for Activities of Daily Living, ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Instrumentelle Aktivität im täglichen Leben (IATL)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Instrumentelle Aktivität im täglichen Leben (IATL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Geriatric Depression Scale (GDS)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Geriatric Depression Scale (GDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Cornell Depression Scale (CDS)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Cornell Depression Scale (CDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hospital Anxiety and Depression Scale deutsche Version (HADS-D)</measure>
    <time_frame>Change from pre-operative (Baseline) up to 365 days after surgery</time_frame>
    <description>Hospital Anxiety and Depression Scale deutsche Version (HADS-D)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Delirium and Post-operative Cognitive Dysfunction (POCD)</condition>
  <arm_group>
    <arm_group_label>Study group:20 patients undergoing two stage liver-operation</arm_group_label>
    <description>Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: 20 patients (ASA class II/III)</arm_group_label>
    <description>Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female and male patients undergoing two stage liver-operations
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Study Group:

        Inclusion Criteria:

          -  Patients undergoing a planned elective in situ split liver operation with following
             resection after approximately ten days with or without additional elective surgery in
             the same session at the University Hospital, Campus Virchow-Klinikum of the Charité -
             University Medicine Berlin

          -  Patients aged greater than or equal to 18 years

          -  Patients of both genders

          -  Offered patient information and written informed consent

          -  No participation in another clinical trial according to the German Drug Law (AMG)
             during the trial and one month before inclusion

        Exclusion Criteria:

          -  Lacking willingness to save and hand out pseudonymised data within the clinical study

          -  Accommodation in an institution due to an official or judicial order

          -  Staff of Charite University hospital Berlin, Virchow Klinikum

          -  Illiteracy

          -  Unability of German language use

          -  Visual and acoustical impairment

          -  core on the mini mental state examination (MMSE) at screening of 23 or less

          -  American Society of Anaesthesiologists (ASA) Classification greater than IV

          -  Ascertained psychiatric disease

          -  Intake of psychotropic drugs (including sleeping pills and Benzodiazepine)

          -  Symptomatic bradycardia

          -  Symptomatic heart rhythm disorder (arrhythmia)

          -  Coronary heart disease Canadian Society of Anaesthesiologists criteria (CSC) stadium
             IV or the presentation of a coronary heart disease that needs intervention

        Control Group:

        Inclusion criteria:

        •Male and female ASA II/III patients, aged ≥ 18 years

        Exclusion Criteria:

          -  Mini-Mental-State-Examination ≤ 23 Points

          -  Neuropsychiatric morbidity, which limits the conduction of the neurocognitive testing

          -  Taking psychothropic drugs (including sleep-inducing drug and benzodiazepine) on a
             regular basis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Spies, MD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte and Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Claudia Spies</investigator_full_name>
    <investigator_title>Department of Anesthesiology and Intensive Care Medicine, CCM and CVK, Charité - Universitätsmedizin Berlin, Germany</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

